View in EDS HTML Full Text PDF Full Text

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.

Saved in:

Bibliographic Details
Title:	FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Authors:	Tillman EJ; Akero Therapeutics, South San Francisco, CA, United States., Rolph T; Akero Therapeutics, South San Francisco, CA, United States.
Source:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2020 Dec 14; Vol. 11, pp. 601290. Date of Electronic Publication: 2020 Dec 14 (Print Publication: 2020).
Publication Type:	Journal Article; Review
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database:	MEDLINE Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	1664-2392
DOI:	10.3389/fendo.2020.601290